



## Myrexis to Participate in Stifel Nicolaus 2011 Orphan Drug One-on-One Conference

SALT LAKE CITY, June 30, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on developing and commercializing novel treatments for cancer, today announced that Adrian Hobden, Ph.D., President and Chief Executive Officer, and Robert Lollini, Chief Financial Officer and Treasurer, will participate in one-on-one meetings with investors registered to attend the Stifel Nicolaus 2011 Orphan Drug One-on-One Conference, to be held July 12, 2011, in New York City.

The conference will not be webcast. Myrexis' most recent investor presentation is available on the Company's Web site, [www.myrexis.com](http://www.myrexis.com).

### About Myrexis, Inc.

Myrexis, Inc. is a biotechnology company focused on developing and commercializing novel treatments for cancer. The Company has leveraged a unique understanding of the genetic causes of human disease to generate a strong pipeline of clinical and pre-clinical product candidates. These include compounds with distinct mechanisms of action and novel chemical structures that have first-in-class and/or best-in-class therapeutic potential. Myrexis is led by an experienced management team with expertise in all aspects of pre-clinical, clinical and commercial drug development.

The Company's oncology program is comprised of two clinical-stage programs and one pre-clinical stage program. Myrexis' pipeline is led by [Azixa](#)<sup>®</sup> (verubulin, MPC-6827), a novel small molecule microtubule destabilizing agent which is targeted to the brain. It is in Phase 2b clinical development for the treatment of glioblastoma multiforme. The Company's Hsp90 program is comprised of novel, potent, small molecule oncology compounds including [MPC-3100](#), a fully-synthetic and orally bioavailable inhibitor of Hsp90 in Phase 1 clinical development and [MPC-0767](#), a novel L-alanine ester pro-drug of MPC-3100, with improved aqueous solubility. [MPC-9528](#), currently in IND-enabling studies, is the lead pre-clinical candidate in the Company's Cancer Metabolism Inhibitor (CMI) program. Myrexis is also evaluating [MPI-0485520](#), an orally bioavailable, potent and selective small molecule inhibitor of type I interferon that is being developed for the treatment of autoimmune diseases.

For more information, please visit [www.myrexis.com](http://www.myrexis.com).

The Myrexis, Inc. logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=9929>

Azixa, Myrexis and the Myrexis logo are trademarks or registered trademarks of Myrexis, Inc. in the United States and foreign countries.

### Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the scheduled participation in the Stifel Nicolaus 2011 Orphan Drug One-on-One Conference, taking place on July 12, 2011, and statements relating to the attributes and potential efficacy, and the expected timing of development and reporting of data of Myrexis' product candidates. These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the factors discussed under the heading "Risk Factors" contained in Myrexis' Form 10-K, for the year ended June 30, 2010, which was filed with the Securities and Exchange Commission on September 13, 2010, as well as any updates to those risk factors filed from time to time in Myrexis' Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myrexis undertakes no duty to update this information unless required by law.

CONTACT: Myrexis, Inc.

Wayne Laslie

Chief Operating Officer

801-214-7822

investor.relations@myrexis.com

The Ruth Group

Stephanie Carrington (investors)

(646) 536-7017

scarrington@theruthgroup.com

Eric Reiss (media)

(646) 536-7032

eriess@theruthgroup.com